Non-invasive, controlled, and sustained release back-of-the-eye therapeutics for sight-threatening diseases such as: severe uveitis, diabetic macular...
There’s no risk. Start your trial today to see profiles of Aciont plus 5054 other startups.
The Medtech Pro Platform has Expanded! Request Demo
Replay LSI2021 Emerging Medtech Summit Play Now
New 2021 Forecasts Released New Data
New 2021 Forecasts Released Learn More
Become a Medtech Market ProLearn More